A Retrospective Audit of Type 2 Diabetes Patients Prescribed Liraglutide in Real-Life Clinical Practice

BACKGROUND: In phase 3 trials, the once-daily human glucagon-like peptide-1 analog liraglutide provided effective glycemic control with low rates of hypoglycemia, weight loss, and reduced systolic blood pressure (SBP) in patients with type 2 diabetes. Through a retrospective clinical audit, the auth...

Descripción completa

Detalles Bibliográficos
Autores principales: Mulligan, Ciara M., Harper, Roy, Harding, Janet, McIlwaine, Werner, Petruckevitch, Ann, McLaughlin, Darren M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687089/
https://www.ncbi.nlm.nih.gov/pubmed/23715814
http://dx.doi.org/10.1007/s13300-013-0025-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687089/
https://www.ncbi.nlm.nih.gov/pubmed/23715814
http://dx.doi.org/10.1007/s13300-013-0025-z

Ejemplares similares